Physician profile
Christopher R Guy
NPI 1386639250
$13,016.28
in general payments reported to CMS, 2019-2025
42 companies · $1,861 in 2025
The $1,861 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,701 · 2020: $1,002 · 2021: $2,079 · 2022: $2,006 · 2023: $1,944 · 2024: $2,424 · 2025: $1,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,228.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,958.94 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $1,417.70 | 2019-2025 | Evenity, Repatha, Prolia |
| Lilly USA, LLC | $1,314.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $1,239.48 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,093.25 | 2019-2025 | Jardiance |
| Pfizer INC. | $731.17 | 2019-2025 | |
| Abbvie INC. | $648.33 | 2019-2024 | |
| Amarin Pharma, INC. | $428.90 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $369.86 | 2022-2024 | |
| Esperion Therapeutics, INC. | $343.18 | 2020-2023 | Nexletol |
| Abbott Laboratories | $320.44 | 2019-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $311.29 | 2020-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $274.80 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $234.94 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $199.36 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,112,392.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Guy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.